Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Treasury Shares: 2017-2024

Historic Treasury Shares for Arcus Biosciences (RCUS) over the last 2 years, with Dec 2024 value amounting to $2.2 million.

  • Arcus Biosciences' Treasury Shares rose 46.67% to $2.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 46.67%. This contributed to the annual value of $2.2 million for FY2024, which is 46.67% up from last year.
  • Per Arcus Biosciences' latest filing, its Treasury Shares stood at $2.2 million for Q4 2024, which was up 46.67% from $1.5 million recorded in Q4 2023.
  • Arcus Biosciences' Treasury Shares' 5-year high stood at $2.2 million during Q4 2024, with a 5-year trough of $653,950 in Q3 2020.
  • In the last 3 years, Arcus Biosciences' Treasury Shares had a median value of $1.5 million in 2023 and averaged $1.7 million.
  • Data for Arcus Biosciences' Treasury Shares shows a peak YoY soared of 62.28% (in 2020) over the last 5 years.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Treasury Shares stood at $738,650 in 2020, then surged by 48.92% to $1.1 million in 2021, then grew by 18.18% to $1.3 million in 2022, then climbed by 15.38% to $1.5 million in 2023, then surged by 46.67% to $2.2 million in 2024.
  • Its Treasury Shares stands at $2.2 million for Q4 2024, versus $1.5 million for Q4 2023 and $1.3 million for Q4 2022.